Showing results (161-170 of 194) with videos related to

Sort By:
Pageof 20
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2019
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III TrialRichard S Finn, Baek-Yeol Ryoo, Philippe Merle, et al.
Liver Cancer|December 15, 2025
Cabozantinib for Hepatocellular Carcinoma in Real-World Practice (CLERANCE): A Prospective, Interventional StudyFrançois Villeret, Mohamed Bouattour, Jean-Frédéric Blanc, et al.
JHEP Reports : Innovation in Hepatology|June 9, 2025
Second-line pembrolizumab for advanced HCC: Meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studiesRichard S Finn, Kangsheng Gu, Xi Chen, et al.
The Lancet. Oncology|May 30, 2021
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trialPeter R Galle, Richard S Finn, Shukui Qin, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 13, 2020
Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2Masatoshi Kudo, Peter R Galle, Josep M Llovet, et al.
The Lancet. Gastroenterology & Hepatology|February 16, 2024
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 studyThomas Yau, Ahmed Kaseb, Ann-Lii Cheng, et al.
The New England Journal of Medicine|May 14, 2020
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular CarcinomaRichard S Finn, Shukui Qin, Masafumi Ikeda, et al.
The Lancet. Oncology|July 7, 2022
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trialRobin Kate Kelley, Lorenza Rimassa, Ann-Lii Cheng, et al.
JHEP Reports : Innovation in Hepatology|January 4, 2021
Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2Masatoshi Kudo, Peter R Galle, Giovanni Brandi, et al.
JHEP Reports : Innovation in Hepatology|March 20, 2023
TACE and conformal radiotherapy <i>vs</i>. TACE alone for hepatocellular carcinoma: A randomised controlled trialCyrille Féray, Loic Campion, Philippe Mathurin, et al.
Pageof 20